Use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AssigneesThe Trustees of the University of Pennsylvania, University of Georgia Research Foundation, Inc.
InventorsDonald A. HARN, JR., Yvonne Paterson, Lisa McEwen
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.
Claims42
A method of treating an infectious disease in a subject having a Th2 phenotypic profile, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein said Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said subject.
A method of preventing an infectious disease in a subject having a Th2 phenotypic profile, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein said Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said subject.
Dependencies are inferred from the claim text.